# IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

> **NCT06819293** · PHASE1 · RECRUITING · sponsor: **Grit Biotechnology** · enrollment: 12 (estimated)

## Conditions studied

- Advanced Clear Renal Cell Carcinoma
- Adult

## Interventions

- **BIOLOGICAL:** IB-T101 injection

## Key facts

- **NCT ID:** NCT06819293
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-06
- **Primary completion:** 2027-12-07
- **Final completion:** 2027-12-07
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06819293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06819293, "IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06819293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*